Imatinib is a tyrosine kinase inhibitor (TKI) which targets BCR-ABL protein in patients with chronic myelogenous leukemia (CML) and c-kit in patients with gastrointestinal stromal tu-mors (GISTs). Skin hypopigmentation is reported during Imatinib therapy. We present a case of CML who developed skin hyperpigmentation in the face during treatment with Imatinib which found chloasma-like appearance
Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) used to treat imatinib-resistant ch...
BACKGROUND: Imatinib mesylate (IM), the first-line treatment of chronic myeloid leukaemia (CML), is ...
Dasatinib is an oral second-generation multitarget tyrosine-kinase inhibitor (TKI) that is efficacio...
Imatinib is a tyrosine kinase inhibitor (TKI) which targets BCR-ABL protein in patients with chronic...
Background: Imatinib mesylate is a tyrosine-kinase inhibitor used as the first-line treatment in chr...
Imatinib mesylate (STI 571; Gleevec; Novartis Pharmaceuticals, Basel, Switzerland) is an orally avai...
BACKGROUNDHypopigmentation is an infrequently reported adverse effect of imatinib mesylate (IM) in c...
Introduction & Objectives: Imatinib mesylate is a tyrosine-kinase inhibitor used as the first-li...
Imatinib mesylate (STI 571, Gleevec) is a potent bcr-abl tyrosine kinase inhibitor. It also inhibits...
Imatinib mesylate is a drug that has been recently approved for the treatment for chronic myeloid le...
Imatinib mesylate is a drug that has been recently approved for the treatment for chronic myeloid le...
We report a rare case of facial hyperpigmentation during imatinib therapy for a gastrointestinal str...
Background: Imatinib mesylate (IM) is a phenylaminopyrimidine that represents the first-line treatme...
Imatinib mesylate is a tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML) throug...
We discuss the case of a 23 years old female with chronic myeloid leukemia. This patient developed k...
Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) used to treat imatinib-resistant ch...
BACKGROUND: Imatinib mesylate (IM), the first-line treatment of chronic myeloid leukaemia (CML), is ...
Dasatinib is an oral second-generation multitarget tyrosine-kinase inhibitor (TKI) that is efficacio...
Imatinib is a tyrosine kinase inhibitor (TKI) which targets BCR-ABL protein in patients with chronic...
Background: Imatinib mesylate is a tyrosine-kinase inhibitor used as the first-line treatment in chr...
Imatinib mesylate (STI 571; Gleevec; Novartis Pharmaceuticals, Basel, Switzerland) is an orally avai...
BACKGROUNDHypopigmentation is an infrequently reported adverse effect of imatinib mesylate (IM) in c...
Introduction & Objectives: Imatinib mesylate is a tyrosine-kinase inhibitor used as the first-li...
Imatinib mesylate (STI 571, Gleevec) is a potent bcr-abl tyrosine kinase inhibitor. It also inhibits...
Imatinib mesylate is a drug that has been recently approved for the treatment for chronic myeloid le...
Imatinib mesylate is a drug that has been recently approved for the treatment for chronic myeloid le...
We report a rare case of facial hyperpigmentation during imatinib therapy for a gastrointestinal str...
Background: Imatinib mesylate (IM) is a phenylaminopyrimidine that represents the first-line treatme...
Imatinib mesylate is a tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML) throug...
We discuss the case of a 23 years old female with chronic myeloid leukemia. This patient developed k...
Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) used to treat imatinib-resistant ch...
BACKGROUND: Imatinib mesylate (IM), the first-line treatment of chronic myeloid leukaemia (CML), is ...
Dasatinib is an oral second-generation multitarget tyrosine-kinase inhibitor (TKI) that is efficacio...